龟龄集胶囊治疗轻中度认知障碍的随机双盲阳性对照多中心非劣效试验方案
本研究为随机、双盲、阳性对照、多中心非劣效设计,纳入348例轻中度认知障碍且属肾虚髓减证患者,随机分为龟龄集胶囊组与阳性对照药组,干预24周,以MMSE和MoCA改善评价认知疗效,并评估安全性及血清乙酰胆碱、乙酰胆碱酯酶、bax、bcl-2等机制指标。
要点
- 龟龄集胶囊拟用于轻中度认知障碍肾虚髓减证,采用非劣效设计对照银杏叶提取物。
- 主要疗效指标为24周MMSE和MoCA评分改善,次要指标包括ADAS-Cog、CDR、ADL及中医证候量表。
- 安全性监测涵盖生命体征、心电图、血尿便常规、肝肾功能及不良事件。
核心结论
- 该试验旨在评价龟龄集胶囊治疗轻中度认知障碍肾虚髓减证的有效性与安全性,若成功可为患者提供可行治疗选择。
研究设计与样本
- 随机、双盲、阳性对照、多中心非劣效临床试验,纳入348例受试者,随机分为试验组174例和阳性对照组174例。
- 试验组每日口服龟龄集胶囊0.6 g一次,并每日三次服用银杏叶提取物模拟剂19.2 mg;对照组每日口服龟龄集胶囊模拟剂0.6 g一次,并每日三次服用银杏叶提取物片19.2 mg。
- 干预周期共24周,分两个阶段。
主要发现
- 原文为研究方案,未报告疗效或安全性结果。
关键数值与推荐
- 主要结局为治疗24周后MMSE和MoCA量表评分改善。
- 次要结局包括ADAS-Cog、CDR总分、ADL总分及中医证候量表评估独立性、日常生活能力和中医证候改善。
- 机制指标监测血清乙酰胆碱、乙酰胆碱酯酶、bax和bcl-2。
- 安全性指标包括生命体征、心电图、全血细胞计数、肝肾功能、尿常规、便常规及不良事件。
临床怎么用
- 该方案针对轻中度认知障碍肾虚髓减证,采用龟龄集胶囊与银杏叶提取物阳性对照进行非劣效评价,结果尚未报告。
局限性
- 原文为研究方案,尚未提供疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of cognitive impairment (CI) is gradually increasing, which has attracted more attention from medical researchers worldwide. Definitive mechanisms of pathogenesis remain elusive, and there are few medications that have been proven effective for CI. The utilization of Chinese herbal medicine has shown positive therapeutic effects for a broad spectrum of diseases, including CI. OBJECTIVE: The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules (GLJC, ) in treating mild-to-moderate CI with Shen (Kidney) and marrow deficiency syndrome. METHODS: This is a randomized, double-blind, positive-controlled, multicenter clinical trial with a noninferiority design that included 348 participants randomly divided into an experimental arm and an active comparator arm. Individuals in the experimental arm (174 cases) took 0.6 g of GLJC once a day and 19.2 mg of Gingko biloba extract mimetic 3 times a day. Individuals in the active comparator arm (174 cases) took 0.6 g of GLJC mimetic once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day. The intervention period included two sessions over 24 weeks. The primary outcome be the effectiveness of GLJC on cognitive improvement after 24 weeks of treatment, which was defined as an increase in the Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) Scale. The secondary outcomes were improvement in independence, daily living ability, and Chinese medicine (CM) syndrome, which were measured with the Alzheimer's disease Rating Scale-Cognitive Project (ADAS-Cog), Clinical Dementia Rating (CDR) Total Score, Activities of Daily Living (ADL) Total Score and the Chinese Medicine Symptom Scale (CM-SS), respectively. Serum acetylcholine, acetylcholinesterase, bax and bcl-2 were monitored to explore the mechanism of GLJC on CI. In addition, safety measures, including vital signs, electrocardiography, laboratory indicators (full blood count, kidney and liver function tests, routine urine test and routine stool test) and adverse events, were also recorded. DISCUSSION: The purpose of this trial is to evaluate the efficacy and safety of GLJC in patients with mild-to-moderate CI with kidney and marrow deficiency syndrome. If successful, the results would provide a viable treatment for patients with mild-to-moderate CI. (Clinical Trials.gov. ID: NCT03647384. Registered on 23 August 2018).
引用
- Liu NY, Pei H, Liu MX, et al. Efficacy and Safety of Guilingji Capsules () for Treating Mild-to-Moderate Cognitive Impairment: Study Protocol for A Randomized, Double-Blind, Positive-Controlled, Multicenter and Noninferiority Trial. Chin J Integr Med. 2020. PMID: 32761337. doi:10.1007/s11655-020-2723-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。